Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    Coronary Arterial Calcium Scans Help Detect Overall Death Risk in the Elderly - (DGNews)
    Angiotensin II blockade and aortic-root dilation in Marfan's syndrome - (N Engl J Med)
    EMEA Recommends Updated Label Warnings for Etoricoxib-Containing Drugs - (DGNews)
    Silent Cerebral Infarction Reported in 10% of Healthy People - (DGNews)
    New Guidance Available for Cardiologists Treating Myocardial Bridging - (DGNews)

    News archive

     Recent webcasts/CME - Cardiology Other
    • Improving Outcomes in Hypertension and Congestive Heart Failure: Focus on New Generation ß-Blockers
    • Antithrombin Therapies: Translating Clinical Trials into Practice
      Update on the Management of Acute Decompensated Heart Failure: Incorporating Treatment Guidelines and Recent Clinical Research Findings into Practice
      The Cardio-Renal Link: Preventing Cardiovascular Disease and Diabetes in Renal Transplant Recipients
      Primary Pulmonary Hypertension

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Response of Pulmonary Artery Intimal Sarcoma to Surgery, Radiotherapy and Chemotherapy: A Case Report
        Pericardial Effusion as the Only Manifestation of Infection with Francisella tularensis: A Case Report
        Caseous Calcification of the Mitral Annulus with Mitral Regurgitation and Impairment of Functional Capacity: A Case Report
        Suspected Association of Ventricular Arrhythmia with Air Pollution in a Motorbike Rider: A Case Report
        Long-Term Event-Free Survival with an Embolised Prosthetic Valve Leaflet in the Thoracic Aorta

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Up to Half of Metabolic Improvement Seen With Rimonabant Is Attributable to Drug Rather Than Weight-Loss Alone: Presented at ACC

        By Olwen Glynn Owen

        ATLANTA, G.A. -- March 15, 2006 -- How patients lose weight can make a substantial difference to their associated cardiometabolic risk factors such as dyslipidemia and glycated hemoglobin levels, researchers reported here.

        In data presented here on March 15th at the 55th Annual Scientific Session of the American College of Cardiology (ACC), researchers compared the relative metabolic benefits of losing weight while taking placebo against the investigational selective cannabinoid type 1 (CB1) receptor blocker rimonabant.

        Rimonabant targets the endocannabinoid system blocking CB1 receptors expressed in the central nervous system and peripherally in adipocytes, liver, muscle cells, and other tissues. In obese individuals, receptors are overactivated, stimulating appetite, increasing food intake, and also influencing lipid and glucose metabolism.

        In patients taking rimonabant, up to half of the improvement seen in some metabolic parameters is attributable to direct effects of rimonabant therapy rather than to the weight loss it causes, researchers say.

        Xavier Pi-Sunyer, MD, director, Obesity Research Center, chief of endocrinology, diabetes, and nutrition, St. Luke's-Roosevelt Hospital, and professor of medicine, College of Physicians and Surgeons, Columbia University, New York, New York, and colleagues presented pooled data from 4 clinical trials that are part of the Rimonabant in Obesity and Related Metabolic Disorders (RIO) program. The trials are RIO-Lipids, RIO-Diabetes, RIO-North America, and RIO-Europe

        Prespecified analyses of the data compared the effects of placebo and rimonabant on levels of high-density lipoprotein (HDL) cholesterol, triglycerides, fasting insulin, hemoglobin A1c (HbA1c), and adiponectin, where patients achieved the same percentage weight loss.

        "In the RIO-lipids trial, HDL was consistently increased and triglycerides reduced to a greater extent with rimonabant than with placebo," Dr Pi-Sunyer noted. "For any level of weight loss, rimonabant achieved an additional improvement in lipid profile. In RIO-diabetes, HBA1c was consistently and significantly reduced more by rimonabant."

        The percentage overall increase in HDL attributable to rimonabant over weight loss alone was 45%, while for adiponectin it was 57%. For the reductions seen in triglycerides, fasting insulin, and HbA1c, it was 46%, 49%, and 55%, respectively.

        "This analysis illustrates the weight-dependent and weight-independent effects of CB1 receptor blockade," Dr. Pi-Sunyer concluded. "It suggests rimonabant has an additional independent benefit at any level of weight loss."

        Commenting on the results, Julian Halcox, MD, vascular physiologist and cardiologist, University College, London, United Kingdom, said rimonabant appears to reduce abdominal fat faster than could be achieved by diet and exercise. "However, despite the apparent added value of rimonabant weight loss, it is important to continue to focus on the need to adopt healthy lifestyle behaviors," he stressed.


        [Presentation title: Improvement of Metabolic Parameters With Rimonabant Beyond the Effect Attributable to Weight Loss Alone: Pooled One-Year Data From the RIO (Rimonabant in Obesity and Related Metabolic Disorders) Program. Abstract 849-3]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send